The Peptide Research Podcast
Educational-based podcast providing the latest in scientific peptide research. We take a complex topic and make it easy for everyone to understand.
https://peptideresearch.us
The Peptide Research Podcast
Episode 90: Retatrutide "The Triple Agonist"
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Click here to join our Discord: Real Peptide Talk
Shop Research Compounds: https://wholesalepeptides.us
Visit our blog: https://peptideresearch.us
Join our Newsletter list: https://peptideresearch.us/newsletter
Affiliate Program: https://wholesalepeptides.us/affiliate-registration-2/
In this episode of the PeptideResearch.us Podcast, hosts Amy Andrews and Todd Collins (AI personas of Peptide Research) examine receptor stacking, the design logic behind multi-receptor incretin compounds, in which a single engineered peptide is built to activate several distinct cell-surface receptors at once. The discussion explores why increasing potency at one receptor reached a ceiling in preclinical and clinical research models, and why investigators turned toward added pathways rather than added signal strength.
The episode details the mechanistic core of receptor agonism, highlighting Glucagon-Like Peptide-1 (GLP-1) receptor signaling and Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor signaling to evaluate what each arm contributes to pancreatic insulin response, gastric emptying rate, and hypothalamic satiety circuits. The conversation breaks down glucagon receptor agonism and hepatic energy mobilization, the single-arm blockade and knockout methodology researchers use to isolate each pathway's contribution, and the receptor cross-talk that makes stacking a signal-balancing exercise rather than an additive one. Semaglutide (GLP-1), Tirzepatide (GLP-2) and Retatrutide (GLP-3) are placed in sequence as single, dual and triple receptor agonists.
Listeners will gain an understanding of what a receptor and an agonist actually are in plain language, why the third receptor arm represented a directional departure rather than an increase in potency, and how rigorous analytical standards like third-party testing and Certificates of Analysis ensure research integrity.
BECOME AN NRG BIOLABS AFFILIATE
Already the person your friends text with peptide questions?
The NRG BioLabs affiliate program gives you your own custom Wholesale Peptides link. Share it with the people already asking. When they order through your link, you earn — and you keep earning every time they reorder. Recurring, not one and done.
No inventory. No minimums. Just your link.
Sign up: https://wholesalepeptides.us/affiliate-registration-2/
Join our exclusive text and email club to receive VIP access to special promotions, limited-time discounts, product launches, and subscriber-only offers.
Join here, its FREE! https://wholesalepeptides.us/insider-club/
Todd, here's the part of the story nobody tells. For about 20 years, the way you made one of these compounds better was to make it stronger. And then that stopped working.
SPEAKER_00It stopped working in a really specific way.
SPEAKER_01Right. And what researchers did next is the whole episode. They quit turning it up. They started adding.
SPEAKER_00We publish new peptide breakdowns several times a week. Tap follow so you catch them all.
SPEAKER_01I'm Amy Andrews, and this is the peptideresearch.us podcast. Todd Collins is with me. Today isn't a compound, it's the idea underneath one. Why three signals instead of one? Todd, what does somebody walk away knowing?
SPEAKER_00Why adding was the move and not multiplying? Get that, and the last 10 years of this field reads like one sentence. One note before we start: all peptides discussed in this podcast relate to research use only. Any references to data from animals, cells, or human studies relate exclusively to scientific literature and not to products from NRG biolabs. These compounds are not approved drugs or dietary supplements and are not for human consumption. Nothing in this podcast is medical advice.
SPEAKER_01Start me at zero.
SPEAKER_00What does a signal even land on? Here's the simple version. Every cell has little docking points on its outside. Each one only takes a molecule shaped to fit it, like a lock that accepts one key. Researchers call a docking point a receptor. And the key is the signal. Whatever fits and turns it. A molecule that fits the lock and switches the cell on, researchers call that an agonist, a key that turns.
SPEAKER_01And the compound everybody's talking about turns three different locks.
SPEAKER_00Three locks, one molecule. That's all anybody means by a triple agonist. One key cut to open three doors.
SPEAKER_01Oh, so it's a chord. You put one hand down and three notes sound at the same moment. And what you hear isn't any one of them, it's the shape they make together.
SPEAKER_00That's better than how I usually say it.
SPEAKER_01Then here's my follow-up. Do three notes just add up? Is this one plus one plus one?
SPEAKER_00No, hold that question because it's where we end up.
SPEAKER_01Okay, so why add at all? Why not take the one signal that worked and lean on it harder?
SPEAKER_00People did try. The first compounds in this family carried a single signal, the note your gut sends out after a meal. Researchers call that one GLP1.
SPEAKER_01Give me that one in a line.
SPEAKER_00It's all about the meal coming in. It tells the pancreas to get ready for sugar, it slows how fast the stomach passes food along, and it reaches the parts of the brain that track having had enough.
SPEAKER_01Three jobs, but all of them on the same side of the ledger.
SPEAKER_00That's the wall exactly. Every one of those jobs is about what comes in, not one of them touches what the body spends. So pushing that signal harder buys you a louder version of the same half.
SPEAKER_01Oh, that's a pit crew where all four people are changing the same tire. They're fast, they're good, car still hasn't been fueled, and nobody standing there is the fuel guy.
SPEAKER_00I'm stealing that one.
SPEAKER_01So my level two question, how did anybody work out which job was missing?
SPEAKER_00By taking pizzas away and watching what changed shape. Here's what a researcher sees on the bench. In animal studies, you can switch off one arm and run the very same experiment. The response doesn't just get smaller, it goes missing in one direction while everything else stays put.
SPEAKER_01So the map got drawn by subtraction.
SPEAKER_00Most of this map did.
SPEAKER_01Okay. Step two, what got added first?
SPEAKER_00A second gut signal. Because your gut doesn't send one note after a meal, it sends two. The second messenger is the other meal messenger. Researchers label it GIP. And what does the second messenger bring that the first one didn't? A different point of contact with the same organ, a second seat at the same table, rather than a second conversation. Tears epitide is the compound built around those two. And on the bench? Same trick. In animal work, the version carrying both messengers reaches the pancreas in a way neither one manages alone.
SPEAKER_01Right. Okay. And step three is the one that raised eyebrows.
SPEAKER_00Step three crossed the ledger. Everything so far was the in column. The third signal is the one that tells the body to open its reserves and spend. Researchers call it glucagon. Retitrutide is the compound described as reaching all three.
SPEAKER_01Two messengers about what's coming in and one about what's going out.
SPEAKER_00That's the whole departure in one line.
SPEAKER_01Okay, Todd. The thing I got wrong for years. My apartment had one lamp. One. Every winter I'd decide the room was too dark, so I'd buy a brighter bulb, then a brighter one. Room stayed gloomy.
SPEAKER_00What fixed it?
SPEAKER_01A friend put a second lamp in the opposite corner, half the wattage of the one I'd been fighting with. Room transformed. The problem was never how bright the bulb was, it was that everything was coming from one place.
SPEAKER_00That's the field's last decade in a living room.
SPEAKER_01So then three is better than two, and two is better than one. Why isn't everybody just stacking to ten?
SPEAKER_00Because every signal you add is another thing that can argue with the others.
SPEAKER_01Oh, it's a group text. Two people is a conversation. At a third, and you've got three conversations happening at once. Add a fourth, and it's a mess nobody can follow. You didn't add one voice, you multiplied the crosstalk.
SPEAKER_00And that's measurable. Two arms in one molecule can push against each other. One can quietly cancel part of what another is doing. So the work isn't collecting receptors, it's tuning how hard each arm pulls. And you learned that the hard way. In the most humbling way there is. Early on, I ran a combination expecting arithmetic, two things that each did something, put them together, and surely you get both. What I got was less than either alone. I spent a week convinced I'd ruined the samples. I hadn't. The two arms were interfering. That week taught me more than any result I've ever had confirmed.
SPEAKER_01Which is exactly why the material in the vial has to be what the label says.
SPEAKER_00That's the floor under all of it. If what you're studying is the balance between three arms, then the last thing you can afford is doubt about what's in there. That's why NRG Biolabs is the foundational partner behind this show. Third-party testing, batch-by-batch documentation, certificates of analysis that state what's actually in the vial. You can see the COAs and view the lab standards at peptidesearch.us.
SPEAKER_01You can't tune a balance you can't trust.
SPEAKER_00Not honestly.
SPEAKER_01Let me pull it together. A receptor is a lock on a cell, and a molecule that fits and turns it is a key. Right. And the first compounds in this family carried one key, GLP1, and everything it does sits on the incoming side, so turning it up just did that half louder.
SPEAKER_00That's the ceiling.
SPEAKER_01So researchers added a second meal messenger, GIP, and then a third signal that works the other direction entirely, glucagon, the spending side. That's the sequence. And the catch is that arms interact, so more isn't automatically better. It has to be balanced.
SPEAKER_00That's a fair summary. Oh, and one last thing that's easy to overlook. Everybody hears three and files it under bigger. It isn't bigger, it's wider. And the next compound out of this field almost certainly won't be four signals, it'll be whichever three make the right shape. Nobody's collecting locks, they're looking for a chord.
SPEAKER_01Oh, I see. It was never about the size of the sound. If you want to go slower, there's a plain English write-up on the GLP compounds at peptidesearch.us. The peptide research section is where I'd start. And if today's breakdown was useful, follow the show. If you're new here, there are 66 episodes in the feed covering nearly every research peptide. Work through them at your own pace. If you like this podcast and want to stay up to date on all the latest peptide research, you can find links to our website, Facebook page, and even our Discord channel in the podcast description below. You can even sign up for our newsletter and get notified every time a new episode rolls out. That's our show. Go put a second lamp in the corner.